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The evolution of articular cartilage repair procedures has resulted in a variety of cell-based therapies that use both
autologous and allogeneic mesenchymal stromal cells (MSCs). As these cells are increasingly available and show
promising results both in vitro and in vivo, cell-based strategies, which aim to improve ease of use and cost-effectiveness,
are progressively explored. The use of MSCs in cartilage repair makes it possible to develop single-stage cell-based
therapies. However, true single-stage procedures rely on one intervention, which will limit cell sources to fraction
concentrates containing autologous MSCs or culture-expanded allogeneic MSCs. So far, it seems both autologous and
allogeneic cells can safely be applied, but clinical studies are still ongoing and little information on clinical outcome is
available. Further development of cell-based therapies may lead to clinical-grade, standardized, off-the-shelf products with
easy handling for orthopedic surgeons. Although as of yet no preclinical or clinical studies are ongoing which explore the
use of induced pluripotent stem cells for cartilage repair, a good manufacturing practice-grade induced pluripotent stem
cell line might become the basis for such a product in the future, providing that cell fate can be controlled. The use of
stem cells in clinical trials brings along new ethical issues, such as proper controls and selecting primary outcome
measures. More clinical trials are needed to estimate detailed risk-benefit ratios and trials must be carefully designed to
minimize risks and burdens for patients while choosing outcome measures that allow for adequate comparison with
results from similar trials. In this review, we discuss the different aspects of new stem cell-based treatments, including
safety and ethical issues, as well as provide an overview of current clinical trials exploring these approaches and future
perspectives.Introduction
Cartilage defects in the weight-bearing joint are a severe
limitation to the patient and pose a significant burden to
society. Symptoms include pain, stiffness, joint effusion and
locking, which cause considerable disability and decrease
quality of life. It is well understood that cartilage defects
need (early) treatment because they have a poor intrinsic
healing capacity and tend to lead to osteoarthritis [1].
Cartilage repair strategies have rapidly evolved over time;
in 1950 the resection of loose and damaged tissue was the
only treatment available. In the late 1980s microfracture* Correspondence: l.a.vonk@umcutrecht.nl
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unless otherwise stated.was introduced, which involves drilling multiple holes in
the subchondral bone to allow an influx of bone marrow
that stimulates natural repair. In 1994, the first results on
autologous chondrocyte implantation (ACI) were pub-
lished [2] and many generations of cell therapy have
followed [3]. In first generation ACI, chondrocytes isolated
from a biopsy of a non-weight bearing location in the knee
were culture-expanded and subsequently implanted under
a periosteal cover. In the second generation, a cover of
collagen or a resorbable biofilm replaced the periosteal
cover. Next, open collagen cell carriers were introduced,
which led to the manufacture of bioactive matrices to im-
prove hyaline cartilage formation. Currently, matrix-based
arthroscopic application and advanced delivery through
bio-airbrush technology are being applied. Much attentionhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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the introduction of characterized cells that show the most
chondrogenic potential and establishing release criteria
and production guidelines.
The mid- to long-term results of ACI have been en-
couraging [2,3]. However, the limitations of this exten-
sive procedure in terms of patient burden and costs have
steered cartilage repair towards single-stage procedures
and off-the-shelf cellular or biomaterial-based products.
The challenge for a single-stage approach lies in obtain-
ing sufficient cells. Due to the low cell number in native
cartilage and the large surface area to volume ratio of
cartilage defects, it is impossible to obtain sufficient au-
tologous chondrocytes without expanding them. There-
fore, the answer could lie in supplementing or replacing
them with multipotent mesenchymal stem or stromal
cells (MSCs; Fig. 1). However, the fate of MSCs in vivo
remains unknown: will they survive or disappear in theFig. 1 Cell-based therapies for cartilage defects have evolved through a fe
cells, one cell type can be used, but the cell expansion can take several we
mesenchymal stromal cells (MSCs) derived from several sources, such as bo
blood (PB) are increasingly used. A single-stage cell-based treatment relies
Options being explored are autologous MSC-rich concentrates, such as a b
adipose tissue (ATVSF) or a combination of rapidly isolated autologous cho
concentrate. An off-the-shelf product that is readily available could consist
line or an embryonic stem cell (ESC) line. ATMSC, adipose tissue-derived m
stromal cell; PBMSC, peripheral blood-derived mesenchymal stromal cell; SMlong-term? Will they all differentiate into chondrocytes
or will some remain as MSCs? Current studies are not
conclusive on these questions; some have suggested
MSCs differentiate and survive in vivo up to 6 months,
while others suggest MSCs have a chondroinductive role
- that is, stimulate cartilage regeneration through trophic
factors while slowly disappearing from the culture [4].
Although it remains unclear what the exact fate of these
MSCs will be in vivo, MSCs of both autologous and
allogeneic origin have increasingly been introduced for
cartilage repair in clinical studies.
The development of an off-the-shelf product to treat
cartilage defects would rely on autologous MSC-rich con-
centrates, allogeneic MSCs or induced pluripotent stem
cell (iPSC) lines. However, rapid developments in the field
make it difficult to evaluate the existing evidence for such
cellular therapies in terms of preclinical and clinical safety
and early efficacy. The purpose of this review is to providew generations with various cell sources. Using expanded autologous
eks. Traditionally, autologous chondrocytes were used, but autologous
ne marrow (BM) adipose tissue (AT), synovium (S) and peripheral
on obtaining sufficient cells within the time frame of a single surgery.
one marrow concentrate (BMC), or the vascular stromal fraction from
ndrons combined with allogeneic MSCs or an autologous MSC-rich
of expanded allogeneic MSCs or an induced pluripotent stem (iPS) cell
esenchymal stromal cell; BMMSC, bone marrow-derived mesenchymal
SC, synovium-derived mesenchymal stromal cell
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gous and allogeneic MSCs for cartilage repair of focal de-
fects. Besides clinical studies, the sources of MSCs, safety
and ethical issues with respect to allogeneic MSCs, the
use of iPSCs and future perspectives are discussed.
Sources for mesenchymal stromal cells
Minimal criteria to define expanded multipotent human
MSCs, as defined by the International Society for Cellular
Therapy, include that they must be plastic-adherent when
maintained in standard culture conditions, express CD105,
CD73 and CD90, and lack expression of CD45, CD34,
CD14 or CD11b, CD79α or CD19 and HLA-DR surface
molecules, and they must be capable of differentiating into
osteoblasts, adipocytes and chondroblasts in vitro [5]. MSCs
can be isolated and expanded from a variety of sources,
such as bone marrow, adipose tissue, synovial membrane,
synovial fluid, umbilical cord blood, peripheral blood, der-
mis, trabecular bone, infrapatellar fat pad, dermis, perios-
teum and muscle. The phenotypic characteristics of MSCs
derived from different sources are similar, but the number
of MSCs and their proliferation and differentiation poten-
tials can differ [6]. Bone marrow is often used as a source
for MSCs (BMMSCs). Although only a small percentage of
its mononuclear fraction consists of BMMSCs, they are
relatively easy to isolate and expand and they have a high
potential for differentiation [7]. The stromal vascular frac-
tion of adipose tissue contains more MSCs (ATMSCs)
compared with bone marrow (as measured in a colony-
forming unit-fibroblasts (CFU-F) assay) and harvesting
adipose tissue is less invasive [8]. ATMSCs show enhanced
rates of proliferation and they can undergo more popula-
tion doublings before senescence [8,9]. However, the
in vitro chondrogenic potential of ATMSCs is lower
compared with BMMSCs in vitro, especially when pellet
cultures are stimulated with transforming growth factor
(TGF)-beta. [9]. The tissue formed by ATMSCs chondro-
genically differentiated with TGF-beta contained less type II
collagen and proteoglycans compared with tissue formed
by chondrogenically differentiated BMMSCs from the same
donors. The exact reason is unknown, but it is suggested
there might be less chondroprogenitor cells present in the
ATMSC population or that the expansion favors clonal
expansion of cells with higher proliferative rates, albeit with
less differentiation potential [9]. However, other studies
have shown a good chondrogenic potential of ATMSCs
when bone morphogenetic protein (BMP)-6 was used,
which may be explained by an altered TGF-beta receptor
and BMP profile of ATMSCs compared with BMMSCs
[10,11].
MSCs derived from the synovial membrane (SMSCs) can
be harvested through an arthroscopic procedure or from
synovial fluid. The amount of SMSCs in synovial fluid is very
low; only about 14 cells per milliliter of synovial fluid fromhealthy donors can form CFU-F colonies. Parts of these
colony-forming cells are considered SMSCs as they can
differentiate into the adipogenic, osteogenic and chondro-
genic lineages. Compared with BMMSCs and ATMSCs, they
have a higher rate of proliferation [12,13]. Sakaguchi and
colleagues showed superior chondrogenic differentiation of
SMSCs compared with donor-matched BMMSCs, ATMSCs
and MSCs from periosteum and skeletal muscle in vitro [14].
SMSCs have also shown potential in in vitro generation of
hyaline cartilage tissue-engineered constructs [15]. Implant-
ation of these in vitro-generated constructs showed good re-
pair of cartilage defects in a pig model with SMSCs isolated
from both immature and mature pigs [16,17].
MSCs can also be isolated from peripheral blood
(PBMSCs) [18]. MSC isolation from blood provides low
cell numbers, but peripheral blood can be easily obtained
in a non-invasive way. Although there is a large variation
in the success rates of isolation of MSCs from umbilical
cord blood (UMSCs), they have good chondrogenic po-
tential [19]. The accessibility of UMSCs along with their
efficient expanding characteristics have made allogeneic
UMSCs the only off-the-shelf cell product for cartilage re-
pair [20]. MSCs can also be isolated from the periosteum,
but the limited availability and complex tissue harvest pro-
cedure forms a barrier for their use. Currently, isolated
BMMSCs and bone marrow concentrates (BMCs) are
most commonly used for treatment of cartilage defects in
a clinical trial setting (Table 1).
One of the concerns with using MSCs for cartilage re-
pair is that if they do differentiate into the chondrogenic
lineage and engraft the new cartilage, they might undergo
terminal differentiation and become hypertrophic, as the
default route of chondrogenic differentiation is terminal
differentiation [21]. This concern is not limited to MSCs
only, as chondrocytes can also undergo hypertrophic
differentiation, which has been found in ACI [22].
Articular cartilage itself, especially the superficial layers,
is also a reservoir for progenitor cells with multilineage
potential [23,24]. Cartilage-derived progenitors even have
a decreased potential for osteogenic and hypertrophic dif-
ferentiation. Although the research on cartilage-derived
progenitor cells is still very limited, a goat study has
proven their ability to repair chondral defects. Williams
and colleagues [24] suggested that about 0.7% of all cells
in cartilage are progenitor cells.
Clinical studies using autologous mesenchymal
stromal cells
Since Wakitani and colleagues [25] performed the first
treatment of full-thickness cartilage defects with autolo-
gous MSCs in 2004, autologous MSCs and MSC-rich
concentrates are increasingly used for cartilage repair
(overview provided in Table 1). Most published results
are obtained from low level (IV or V) evidence studies
Table 1 Overview of clinical studies applying autologous mesenchymal stromal cells to a cartilage defect
Cell type Study type Number of patients Follow-up Results Reference
BMMSC Case report 2 5 years Clinical improvement and defect fill with fibrocartilage [25]
BMMSC Case report 1 1 year Bone and cartilage repair [26]
BMMSC Case report 3 17-27 months Clinical improvement and defect fill with fibrocartilage [27]
BMMSC Case report 1 12 months Clinical improvement and defect fill with hyaline tissue [28]
BMMSC Case series 5 12 months Clinical improvement and defect fill [29]
BMMSC Case report 2 31 months Clinical improvement and defect fill [30]
BMC Case series 48 4 years Clinical improvement and defect fill [31,32]
BMC Case series 20 24 months Bone and cartilage repair [33]
BMC Case series 5 12 months Defect fill with hyaline to fibrocartilaginous tissue [34]
BMC Case series 54 5 years Clinical improvement and good integration of repair tissue [35]
BMC Case series 15 2 years Clinical improvement and defect fill with hyaline tissue [36]
BMC and ACy Case series 40 Interim results 1 year Clinical improvement and defect fill with hyaline tissue [37] NCT01041885
SMSC [16,17]
BMMSC Comparative study 36 (total 72) 24 months Clinical improvement, defect fill with hyaline tissue [38]
BMC Comparative study 25 (total 81) 36 months Clinical improvement and defect fill with hyaline tissue [39]
PBMSC or BMC Comparative study 25 PBMSC, 21 BMC 5 years Clinical improvement and defect fill for both groups [40]
BMMSC Case series 25 12 months NCT00891501
BMMSC Case series 6 12 months NCT00850187
BMC Case series 140 36 months NCT02005861
BMC Case series 50 12 months NCT01159899
ATSVF Comparative study 40 24 months NCT02090140
ATMSC Comparative study 30 18 months NCT01399749
BMMSC Comparative study 50 in total 5 years NCT00885729
ACy autologous chondrocyte, ATMSC adipose tissue-derived mesenchymal stromal cell, ATSVF adipose tissue stromal vascular fraction, BMC bone marrow concentrate, BMMSC bone marrow-derived mesenchymal
stromal cell, PBMSC peripheral blood-derived mesenchymal stromal cell, SMSC synovium-derived mesenchymal stromal cell
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Nejadnik and colleagues [38] compared the implantation
of BMMSCs (36 patients) with first-generation ACI (36
matched patients) in a cohort study (evidence level III).
Based on clinical and subjective improvement up to 2 years
postoperatively, it was concluded that BMMSCs are as
effective as chondrocytes for articular cartilage repair.
Histological evaluation of biopsies taken from a few
patients (four BMMSC, three ACI) showed hyaline-like
cartilage tissue and no abnormal calcification or necrosis.
Interestingly, patients younger than 45 years scored better
than patients aged over 45 years in the ACI group, while
age did not make a difference in the BMMSC group. Fol-
lowing several case series, Giannini and colleagues [31-33]
reported on a one-step approach to treat osteochondral
talar dome defects and compared a MSC-rich BMC (25
patients) with ACI (10 patients) and an arthroscopic ACI
(46 patients) (evidence level IV) [39]. As in the previously
described study, similar clinical improvement was ob-
served, and magnetic resonance imaging (MRI) and histo-
logical evaluation showed complete defect fill with
hyaline-like cartilage tissue in the majority of patients.
Only one study compared the use of two MSC-based
treatments for cartilage repair [40]. In this study, 21 pa-
tients were treated with BMCs and 25 with PBMSCs. Clin-
ical improvement was found in a total of 40 patients, in
which the patients treated with PBMSCs showed superior
results compared with the patients treated with BMCs.
Poor results were found for four patients in the BMC group
and two patients in the PBMSC group. Although MRI was
also performed in this study, no MRI results were reported.
Although only two studies directly compared MSC-based
treatments with ACI [38,39], the conclusions from these
studies do suggest that MSCs are a promising cell source
for cartilage repair. This is supported by the findings in the
level IV and V evidence studies that used BMMSCs or
BMC for cartilage repair; all have reported clinical improve-
ment with a follow-up period ranging from 1 year to 5 years
[25,27-32,35,36,38-40]. The studies that included MRI ana-
lysis in their outcome measures reported complete defect
fill [27-29,31-33,35,36] and mostly congruity with the native
cartilage [29,35]. Histological evaluation of biopsies showed
the reparative tissue was hyaline-like cartilage [28,33,35,
36,38,39], fibrocartilage [25,27,31,32], or a mixture of both
[26,34].
Several other studies using autologous MSCs or concen-
trates are still ongoing, including two studies using ATMSCs
to treat cartilage defects (Table 1; NCT01399749 and
NCT02090140). So far, ATMSCs have only entered the
preclinical phase in cartilage repair. In clinical use, con-
centrated ATMSCs have been injected intra-articularly for
treatment of osteoarthritis [41,42]. SMSCs have been used
in preclinical studies, which gave promising results
[16,17]. The tissue-engineered construct made by SMSCsas described in those preclinical studies is currently being
explored in an investigator-driven phase I/II clinical trial
in a small cohort in Japan.
Thus, only clinical results using expanded undifferenti-
ated BMMSCs, PBMSCs or BMCs (bone-marrow derived
buffy coat or the mononuclear fraction of bone marrow)
are reported. Pre-differentiated MSCs have not been used
as yet. Although MSCs and MSC-rich concentrates are
promising for cartilage repair, a lack of comparative stud-
ies confines a prediction to what the optimal cell source
for MSC-based cartilage repair would be. Moreover, MSCs
and BMCs have been implanted using various cell carriers,
passages and doses (sometimes even not reported; Tables 2
and 3), so much remains to be investigated and learned.
Safety considerations using allogeneic
mesenchymal stromal cells
It took until 2010 before the first clinical study exploring
the use of allogeneic MSCs for cartilage repair started
[20], probably due to the unknown risk of an immune re-
sponse to allogeneic cells. MSCs have been shown to have
low immunogenicity based on the lack of expression of
markers such as CD45 and CD34 and HLA-DR surface
molecules [43]. In addition, they are known to interact
with immune cell populations and modulate the host im-
mune responses [43]. Because of the immunosuppressive
properties of MSCs, allogeneic MSCs are currently infused
intravenously for the treatment of steroid-resistant graft-
versus-host disease, acute respiratory distress syndrome
and Crohn’s disease in clinical trials. However, as it
remains unclear what the exact fate of these MSCs is
in vivo, it cannot be excluded that the MSCs differentiate,
leading to a loss in their immune-modulating property
and a change in their immunogenicity [44]. Several pre-
clinical studies in rabbits, pigs and goats showed effective
cartilage repair after implantation of allogeneic MSCs in
cartilage defects without any adverse events or rejection
[17,45,46]. Moreover, no adverse events were reported
when fully differentiated allogeneic chondrocytes or allo-
geneic cartilage pieces were transplanted in several animal
and human clinical trials [47,48], possibly due to the im-
mune privileged character of cartilage as it is avascular
and has no lymphatic system. It has to be noted that
cartilage defects are often debrided, which can cause pene-
tration of the subchondral bone, allowing an influx of
bone marrow. This might become a concern for using
pre-differentiated allogeneic cells or allogeneic iPSCs.
Clinical studies using allogeneic mesenchymal
stromal cells
Only a few clinical trials have been initiated using allo-
geneic MSCs for cartilage repair (Table 4). In Korea, a
phase III clinical trial comparing allogeneic UMSCs with
sodium hyaluronate (CARTISTEM®, MEDIPOST, Korea)
Table 2 Details on mesenchymal stromal cells used in clinical studies
Cell type Cell carrier Cell dose Expansion medium Passage Characterization Reference
BMMSC Collagen gel 5 × 106/ml αMEM, 15% AS Single passaged CD73, CD90, CD105+,
CD14, CD34, HLA-DR-
[25,27,28]
BMMSC Hydroxyapatite ceramic 1.15 × 106 in total DMEM, 15% AS Single passaged [26]
BMMSC Fibrin glue with periosteum 2 × 106 cells/cm2 DMEM, 10% FBS, 50 μg/ml AA2P, 1% antibiotic-antimycotic Single passaged CD90, CD105+, CD14, CD34- [38]
BMMSC Platelet-rich fibrin gel 2 × 106 cells/cm2 DMEM, 10% FBS, 1% pen/strep Single passaged CD73+, CD34, CD45- [29]
BMMSC Collagen scaffold DMEM, 10%, FBS 1% pen/strep Passaged [30]
BMMSC Membrane NCT00885729
BMMSC Periosteum Passaged NCT00891501
BMMSC Type I collagen scaffold Passaged NCT00850187
PBMSC Collagen membrane 1.25-5.2 × 106 N/A Unpassaged [40]
ATMSC Periosteum Passaged NCT01399749
SMSC SMSC TEC [16,17]
UMSC Sodium hyaluronate Passaged [20] NCT01041001
BMMSC and AC Fibrin glue 2 × 106 cells/cm2 αMEM, 5% platelet lysate Passage 3 CD73, CD90, CD105+,
CD45, CD34, CD11b, CD14,
CD31, CD79, CD19, HLA-DR-
[3,46] NCT02037204
αMEM alpha minimal essential medium, AA2P L-ascorbic acid 2-phosphate sesquimagnesium salt hydrate, AC autologous chondrons, AS autologous serum, ATMSC adipose tissue-derived mesenchymal stromal cell,
BMMSC bone marrow-derived mesenchymal stromal cell, DMEM Dulbecco’s modified Eagle medium, FBS fetal bovine serum, N/A not applicable, PBMSC peripheral blood-derived mesenchymal stromal cell, Pen/strep
penicillin/streptomycin, SMSC synovium-derived mesenchymal stromal cell, TEC tissue engineered construct, UMSC umbilical cord blood-derived mesenchymal stromal cell
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Table 3 Details on bone marrow concentrates used in clinical studies
Type Cell carrier Harvest location Amount
harvested
Amount used Reference
BMC Collagen membrane Ilium 27 ml 0.5-2.7 × 106 cells [40]
BMC Collagen powder or hyaluronic
acid membrane and platelet gel
Posterior iliac crest 60 ml 2 ml 10 × concentrated BM [31-33,39] NCT02005861
BMC Type I collagen scaffold Iliac crest 60 ml [34]
BMC Collagen membrane Ipsilateral iliac crest 60 ml 4-6 × concentrated BM,
CFU-F/ml 2,000-5,700
[35]
BMC Collagen I/III membrane Ilium 30 ml [36]
BMC Protein matrix in collagen
hydroxyapatite scaffold
NCT01159899
BMC and ACy INSTRUCT scaffold [37] NCT01041885
ATSVF Collagen scaffold Infrapatellar
fat pad
5 cc NCT02090140
ACy autologous chondrocyte, ATSVF adipose tissue stromal vascular fraction, BM bone marrow, BMC bone marrow concentrate, CFU-F colony-forming unit-fibroblasts
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100 patients with articular cartilage defects were in-
cluded in this study to assess the safety and efficacy with
a follow-up of 48 weeks (NCT01041001). The safety of
using allogeneic UMSCs was confirmed and histological
analyses showed repair with hyaline-like tissue [20].
Currently, the study is expanded with a follow-up time
of 60 months (NCT01626677). CARTISTEM® has re-
cently been introduced in a phase I/II clinical trial in
the USA (NCT01733186).
A clinical trial using an allograft SMSC-based tissue
engineered construct is under review by the Pharma-
ceutical and Medical Devices Agency of Japan for pos-
sible commercialization.
In the Netherlands, we have started an investigator-driven
phase I/II clinical trial (IMPACT) using a mixture of rapidly
isolated autologous chondrocytes with their pericellular
matrix (chondrons) combined with allogeneic BMMSCs in
fibrin glue [3,46] (NCT02037204). The inclusion of the
targeted 35 patients has recently been completed and no
treatment-related adverse events have been observed (the
patients are currently at a follow-up ranging from 7 months
to 1 year after surgery). Preliminary safety monitoring has
not shown any immunological concerns while clinical
outcome and structural outcome as measured by MRI andTable 4 Clinical studies applying allogeneic mesenchymal str
Cell type Number of patients Follow-up Results
UMSC 104 48 weeks Safe applic
UMSC 103 60 months
UMSC 12 24 months
SMSC
BMMSC with AC 35 1 year Preliminary
AC autologous chondrons, BMMSC bone marrow-derived mesenchymal stromal cell
blood-derived mesenchymal stromal cellsecond-look arthroscopies have demonstrated encouraging
initial results.
Induced pluripotent stem cells
The ability to generate iPSCs from somatic cells has cre-
ated new opportunities for the field of cartilage repair.
Just like human embryonic stem cells (hESCs), they
show unlimited self-renewal and they can differentiate
into all three germ layers (ectoderm, endoderm and
mesoderm), but without having the ethical concerns
associated with hESCs. However, there are some differ-
ences reported in the efficiency to differentiate towards
several lineages, such as neural, cardiovascular and
hemangioblastic lineages. iPSCs can be generated by
overexpressing transcription factors associated with
pluripotency, such as Oct3/4, Klf4, c-myc and Sox2. The
genetic reprogramming to induce pluripotency is a lim-
iting factor for clinical use as the most efficient viral
transductions lead to integration of viral DNA into the
chromosome. Reprogramming without causing genetic
change has gained recent interest and several non-viral
methods using microRNA, synthetic messenger RNA
and proteins have been developed.
In vitro studies showed chondrogenic differentiation
and cartilage formation by iPSCs derived from humanomal cells to a cartilage defect for repair
Reference
ation and repair with hyaline tissue [20] NCT01041001
NCT01626677
NCT01733186
[16,17]
: safe application and repair with hyaline tissue [3,46] NCT02037204
, SMSC synovium-derived mesenchymal stromal cell, UMSC umbilical cord
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chondrocytes [50]. One study showed that overexpres-
sion of Oct4 and Klf4 (two-factor reprogramming) was
successful in generating iPSCs from murine neural stem
cells, which were capable of differentiating into the
chondrogenic lineage [51]. Differentiation of iPSCs to
the chondrogenic lineage was efficient if they were first
differentiated towards an MSC-like intermediate pheno-
type [52,53].
Chondrogenic cells were also generated directly from
somatic cells by reprogramming with c-Myc, Klf4 and the
chondrogenic transcription factor Sox9. The cells were
non-tumorigenic and had stable karyotypes, and they
formed homogeneous hyaline cartilage [54,55].
Diekman and colleagues [56] generated iPSCs from
murine fibroblasts and purified the type II collagen-driven
green fluorescent protein-expressing cells upon chondro-
genic differentiation to obtain a uniformly differentiated
cell population. This cell population was subsequently
successfully used to fill a defect in an in vitro chondral de-
fect model. As it was reported that iPSCs can differentiate
easier along the lineages related to the cell type of
origin, iPSCs derived from several chondrocyte donors
were investigated for their chondrogenic potential [57].
Indeed, these reprogrammed chondrocytes could be
differentiated into cartilage-producing chondrocytes
more easily than fibroblast-derived iPSCs. However, one
of the chondrocyte-derived iPSC lines showed higher
aggrecan gene expression level compared with the other
generated iPSC cell lines, while no differences were ob-
served in gene expression levels of other chondrogenic
markers. So even the chondrogenic potential of iPSCs
differs between different iPSC lines.
Although safety precautions and new iPSC generation
techniques have been introduced, it remains to be shown
that cell fate and phenotype can be controlled without
having the risk of teratoma formation. Thus, before pre-
clinical and clinical tests can be done, there is a need for
reliable control of the cell fate.
Ethical considerations in stem cell-based
treatments
The design and initiation of clinical trials using stem
cells for cartilage repair is ethically challenging [58].
Only a limited number of case reports and clinical trials
using a stem cell-based treatment have been reported.
Moreover, the end product that is used is often poorly
described - critical information on culture methods (if
applicable), cell characterization, source, concentration,
and carrier are often missing. All these factors have a
pronounced influence on the behavior of cells and
could, therefore, also affect clinical outcomes of stem
cell-based treatments. In the case of BMCs it should
be reported how much bone marrow was initiallyharvested, how much concentrate is used for the treat-
ment and what the CFU/ml is, such as provided
by Gobbi and colleagues [35]. The limited number of
studies and the lacking information make it hard to ac-
curately predict the risks and clinical outcomes of MSC-
based treatments. There are risks associated with the
intervention and the harvesting procedures of MSCs,
while the invasiveness of both procedures may vary
depending on the MSC source and treatment strategy.
A risk-benefit ratio should be assessed, as the risk to
participants must be proportional to the anticipated
benefits. In the relatively new field of MSC-based treat-
ment for cartilage defects, it is hard to predict clinical
outcomes and thus benefits for the first individual pa-
tients in a clinical study, while the scientific and societal
relevance is increased. To be able to assess accurate
risk-benefit ratios, negative results should also be pub-
lished. Moreover, including all data in the European
group for Blood and Marrow Transplantation database
will enable the risk-benefit assessment for cellular
therapy products [59].
Uniform use of outcome parameters facilitates the
comparison of treatments used in various clinical stud-
ies. There is still an ongoing discussion whether struc-
tural cartilage regeneration, clinical improvement or a
combination should be the main outcome measure.
Clinical improvement is undoubtedly an important out-
come measure, but placebo and nonspecific effects can
affect the patient’s perspective and it has been suggested
that clinical improvement does not necessarily correlate
with cartilage tissue regeneration. A second-look arth-
roscopy and histological evaluation of a biopsy is the
golden standard to evaluate structural parameters of
cartilage regeneration, but is relatively invasive for pa-
tients. A less invasive, but also less detailed and inform-
ative, measure is MRI. However, there is only a weak
correlation between clinical and MRI outcomes, so the
challenge remains to determine how clinical and struc-
tural results may correlate [60].
Another important ethical consideration is the selection
of an appropriate control group. For a double-blinded ran-
domized controlled trial, the use of a placebo, or in the
case of cartilage repair a sham intervention, could be ne-
cessary. In the case of MSC-based cartilage repair, the use
of a sham group is unacceptable as there is an alternative
treatment that provides medical advantage (ACI) and the
risks and invasiveness of sham procedures are dispropor-
tionate to the social value. ACI can serve as a control.
However, it is impossible to compare the two-stage ACI
treatment to a single-stage procedure without introducing
a sham intervention. It is also unacceptable to test safety,
tolerability, pharmacokinetics and pharmacodynamics of
MSC-based cell products on healthy volunteers, as the
risks and burdens of the intervention are too high.
Note: This article is part of a thematic series on Biology
and clinical applications of stem cells for autoimmune and
musculoskeletal disorders, edited by Christian Jorgensen and
Anthony Hollander. Other articles in this series can be found at
http://www.biomedcentral.com/series/MSC.
Vonk et al. Stem Cell Research & Therapy  (2015) 6:94 Page 9 of 11Considerations and future perspectives
With respect to the technovolution of articular cartilage
repair strategies, it is expected that more single-stage proce-
dures will emerge that utilize a stem cell-based approach as
well as procedures using instructive biomaterials that may
facilitate the differentiation of MSCs into the chondrogenic
lineage. Single-stage cell-based cartilage repair reduces the
burden on patients and eliminates a costly cell-expansion
phase. As a true one-stage strategy requires only one surgi-
cal intervention, additional biopsies apart from the surgery
of any kind to isolate chondrocytes or MSCs should be
avoided. This suggests that cells should either be isolated
during the time frame of one surgery or allogeneic cells
should be used.
It is common to select MSCs from a heterogeneous
starting population based on their ability to attach and ex-
pand on plastic. During culture, they overgrow the other
cell types, leading to a culture-expansion-driven isolation
of MSCs. For a single-stage strategy this would not be
possible if autologous cells were to be used. MSCs could
also be isolated by fluorescence-activated cell sorting
(FACS) based on their cell surface markers. Antibodies
used for the FACS sorting should comply with good
manufacturing practice (GMP) regulations for clinical use,
which at present is quite expensive. Moreover, as the
amount of MSCs is relatively low in adult tissues, it is un-
likely sufficient MSCs could be isolated in this way for a
single-stage approach. What is more, relatively little infor-
mation is available on freshly FACS-isolated MSCs with
respect to their behavior and chondrogenic capacity. This
might differ from expanded MSCs as expansion can favor
certain clones. To overcome this problem, autologous
bone marrow concentrate (containing the mononuclear
cell fraction) and the stromal vascular fraction of adipose
tissue are being investigated. Just like the cartilage repair
capacities of MSCs from different tissue types are not yet
compared in clinical studies, there is no real comparative
clinical study on concentrated cell fractions versus MSCs.
However, several studies confirmed fibrocartilaginous to
hyaline-like repair tissue in cartilage defects treated with
BMC [31-37,39,40]. Thus, it might be valuable to investi-
gate the outcomes of concentrated cell fractions compared
with expanded MSCs, as allogeneic MSCs are also a viable
option for cartilage repair.
Allogeneic MSCs have safely been used in clinical studies.
The applicability of allogeneic MSCs opens up the possibility
to generate an off-the-shelf cell product for cartilage repair.
A clinical grade standardized off-the-shelf product with easy
handling for orthopedic surgeons would create a consider-
able advantage. Critical steps in the development of such a
product would be to choose the origin of the cells and the
cell carrier, as both factors have a pronounced effect
on chondrogenesis and cartilage formation. Besides these
factors, such a product should contain cells with properpotency from a single cell line to avoid differences in clinical
outcomes due to batch variation. Finally, the production
process should be performed in a GMP-licensed cell therapy
facility with easy access to the treating hospitals. Although
as of yet no preclinical or clinical studies are ongoing
which explore the use of iPSCs for cartilage repair, a
GMP-grade iPSC cell line might become the basis for
such a product in the future, providing that cell fate can
be controlled. A hESC cell line would also still possess
this therapeutic potential, but would bring along some
ethical concerns. Thus far, both autologous MSC-rich
concentrates such as BMC and the vascular stromal
fraction from adipose tissue, and allogeneic MSCs seem
promising cell sources that are currently being used for
single-stage treatments of cartilage defects in clinics.Conclusion
Implantation of MSCs is a realistic and promising approach
for the treatment of cartilage defects, which is increasingly
being introduced in early clinical trials. To make optimal
use of these different cell types, considerable work remains
to be done in terms of finding the optimal cell source, cell
dose and carrier along with understanding the (long-term)
cell fate and new ethical issues these cell types bring along.Abbreviations
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